Last updated on April 19, 2014 at 13:20 EDT

Latest AiCuris GmbH & Co. KG Stories

2012-11-27 08:28:28

WUPPERTAL, Germany, November 27, 2012 /PRNewswire/ -- Cross-Reference: More Informations are available at: http://www.presseportal.de/pm/106935 AiCuris announced today that it has started the second clinical efficacy trial with pritelivir (AIC316), its novel anti-herpes simplex virus (HSV) drug in development. After the first trial showed a high efficacy of pritelivir against genital herpes, the present trial AIC316-01-II-02 (NCT01658826, http://www.clinicaltrials.gov) is...